UroGen Pharma (URGN) Research & Development (2016 - 2025)
Historic Research & Development for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $14.0 million.
- UroGen Pharma's Research & Development rose 2336.42% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.7 million, marking a year-over-year increase of 2639.25%. This contributed to the annual value of $57.1 million for FY2024, which is 2527.95% up from last year.
- Per UroGen Pharma's latest filing, its Research & Development stood at $14.0 million for Q3 2025, which was up 2336.42% from $18.9 million recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Research & Development registered a high of $19.9 million during Q1 2025, and its lowest value of $10.2 million during Q3 2023.
- Its 5-year average for Research & Development is $13.5 million, with a median of $12.7 million in 2022.
- Per our database at Business Quant, UroGen Pharma's Research & Development soared by 4956.82% in 2021 and then crashed by 2193.13% in 2023.
- Over the past 5 years, UroGen Pharma's Research & Development (Quarter) stood at $13.1 million in 2021, then grew by 10.66% to $14.5 million in 2022, then decreased by 21.93% to $11.3 million in 2023, then soared by 31.78% to $14.9 million in 2024, then decreased by 5.95% to $14.0 million in 2025.
- Its Research & Development was $14.0 million in Q3 2025, compared to $18.9 million in Q2 2025 and $19.9 million in Q1 2025.